SeqCure Immunology is a Stockholm-based immunotherapy startup that develops SeqCureNEO, a curative, personalized cell therapy for treatment of advanced-stage cancer.
SeqCure Immunology is a Stockholm-based company that develops SeqCureNEO, a personalized cell therapy product for the treatment of advanced-stage cancer.
The SeqCureNEO cell product is created from the patient's own immune cells, isolated from a blood sample. Through our proprietary culturing process, the cells are cultured and modified to react against the patient's individual tumor mutations. No genetic engineering - only enrichment and strengthening of the weak anti-tumor immune response that already exists in the patient.
SeqCure Immunology is currently seeking investors to fund the final pre-clinical developement of SeqCureNEO in preparation for its First-In-Man clinical trial.
2021-09-01
Every human is unique, and so is every tumor. SeqCureNEO is a personalized cell therapy product, tailor-made from the mutation profile of each individual patient. From a blood sample, immune cells are isolated, stimulated, enriched, cultured - and returned to the patient. Our proprietary manufacturing process ensures that only the tumor-reactive cells are allowed to grow, thereby maintaining specificity and potency while minimizing side effects.
In order to identify tumor-driving mutations, small samples of blood and tumor are needed.
If tumor tissue samples have been stored from previous surgery and/or biopsy sampling, those samples may be used in this step, alleviating the need for additional invasive procedures.
From the blood- and tumor tissue samples, DNA and RNA are extracted and analysed using deep sequencing technology.
In order to identify tumor-driving mutations, small samples of blood and tumor are needed.
If tumor tissue samples have been stored from previous surgery and/or biopsy sampling, those samples may be used in this step, alleviating the need for additional invasive procedures.
From the blood- and tumor tissue samples, DNA and RNA are extracted and analysed using deep sequencing technology.
Using advanced bioinformatic algorithms, the patient's unique tumor-driving mutations are identified from the DNA- and RNA sequences analysed in the previous step.
Neoantigen peptides (small proteins) that correspond to the identified tumor-driving mutations are produced.
From a blood sample, immune cells are isolated and expanded in a cleanroom laboratory. During this phase, the cells are enriched and carefully monitored to ensure that potency as well as anti-tumor specificity is maintained throughout the culture.
Following purification and rinsing, the SeqCureNEO cell product is now ready to be administered to the patient. The transfer procedure is similar to an ordinary blood transfusion.
SeqCure Immunology is a member of the KI Innovations DRIVE incubator. Our lab and main office are located on the Karolinska Institutet campus area in Stockholm, Sweden.
Want to learn more about SeqCureNEO?
Fill out the form below (or send us an email) and we will get back to you shortly.